Boundless Bio (BOLD) Change in Accured Expenses (2023 - 2026)

Boundless Bio (BOLD) has reported Change in Accured Expenses for 4 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 47.43% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $646000.0 (up 158.83% YoY), while the FY2025 annual figure was $1.6 million, up 110.84% from the prior year.
• Change in Accured Expenses slipped to -$3.1 million in Q1 2026 per BOLD's latest filing, from $977000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.8 million in Q3 2024 and bottomed at -$3.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $77000.0 across 4 years, with a median of $855000.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 147.75% in 2025 and fell as far as 891.9% in 2025.
• Boundless Bio's Change in Accured Expenses stood at $549000.0 in 2023, then plunged by 472.68% to -$2.0 million in 2024, then surged by 147.75% to $977000.0 in 2025, then sank by 414.33% to -$3.1 million in 2026.
• Business Quant data shows BOLD's Change in Accured Expenses at -$3.1 million in Q1 2026, $977000.0 in Q4 2025, and $1.5 million in Q3 2025.